{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:12:46Z","timestamp":1791090766470,"version":"4.1.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2005,10]]},"DOI":"10.1016\/j.revmed.2005.06.011","type":"journal-article","created":{"date-parts":[[2005,8,12]],"date-time":"2005-08-12T07:38:16Z","timestamp":1123832296000},"page":"812-815","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Les inhibiteurs du prot\u00e9asome"],"prefix":"10.1016","volume":"26","author":[{"given":"J.","family":"Alexandre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2005.06.011_bib1","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1200\/JCO.2005.11.030","article-title":"Proteasome inhibition as a novel therapeutic target in human cancer","volume":"23","author":"Rajkumar","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.revmed.2005.06.011_bib2","first-page":"2505","article-title":"A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies","volume":"8","author":"Aghajanian","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.revmed.2005.06.011_bib3","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.revmed.2005.06.011_bib4","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.revmed.2005.06.011_bib5","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1365-2141.2005.05540.x","article-title":"Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma","volume":"129","author":"Jagannath","year":"2005","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.revmed.2005.06.011_bib6","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma","volume":"23","author":"Goy","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.revmed.2005.06.011_bib7","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","article-title":"Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma","volume":"23","author":"O'Connor","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.revmed.2005.06.011_bib8","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1073\/pnas.0401563101","article-title":"Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib","volume":"101","author":"Sun","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.revmed.2005.06.011_bib9","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1200\/JCO.2004.02.106","article-title":"Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer","volume":"22","author":"Papandreou","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.revmed.2005.06.011_bib10","first-page":"640","article-title":"Phase 2 study of bortezomib\u00b1docetaxel in previously treated patients with advanced non-small cell lung cancer","volume":"23","author":"Fanucchi","year":"2004","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.revmed.2005.06.011_bib11","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1200\/JCO.2004.10.155","article-title":"Phase II trial of bortezomib for patients with advanced renal cell carcinoma","volume":"22","author":"Kondagunta","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.revmed.2005.06.011_bib12","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1002\/cncr.21108","article-title":"A phase II study of bortezomib in the treatment of metastatic malignant melanoma","volume":"103","author":"Markovic","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.revmed.2005.06.011_bib13","first-page":"334","article-title":"Phase I\/II trial of bortezomib in patients with unresectable hepatocellular carcinoma (HCC)","volume":"23","author":"Hegewisch-Becker","year":"2004","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.revmed.2005.06.011_bib14","first-page":"13","article-title":"A phase II study of the proteasome inhibitor PS-341 in patients (pts) with metastatic breast cancer (MBC)","volume":"23","author":"Brown","year":"2004","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.revmed.2005.06.011_bib15","first-page":"222","article-title":"A phase II trial of the proteosome inhibitor PS-341 (bortezomib; Velcade) in patients with metastatic colorectal cancer","volume":"23","author":"Mackay","year":"2004","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.revmed.2005.06.011_bib16","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1182\/blood-2004-07-2911","article-title":"Phase I trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies","volume":"105","author":"Orlowski","year":"2005","journal-title":"Blood"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866305003127?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866305003127?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:14:17Z","timestamp":1759335257000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866305003127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10]]},"references-count":16,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["S0248866305003127"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2005.06.011","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2005,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Les inhibiteurs du prot\u00e9asome","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2005.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}